Atul Deodhar

5.8k total citations · 3 hit papers
125 papers, 3.0k citations indexed

About

Atul Deodhar is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Atul Deodhar has authored 125 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Rheumatology, 69 papers in Immunology and 46 papers in Hematology. Recurrent topics in Atul Deodhar's work include Spondyloarthritis Studies and Treatments (103 papers), Rheumatoid Arthritis Research and Therapies (75 papers) and Psoriasis: Treatment and Pathogenesis (66 papers). Atul Deodhar is often cited by papers focused on Spondyloarthritis Studies and Treatments (103 papers), Rheumatoid Arthritis Research and Therapies (75 papers) and Psoriasis: Treatment and Pathogenesis (66 papers). Atul Deodhar collaborates with scholars based in United States, Germany and United Kingdom. Atul Deodhar's co-authors include Désirée van der Heijde, Abhijeet Danve, Jürgen Braun, Joachim Sieper, Xenofon Baraliakos, Brian Porter, Hanno B. Richards, Keith S. Kanik, Dona Fleishaker and Sujatha Menon and has published in prestigious journals such as The Lancet, JAMA and Annals of Internal Medicine.

In The Last Decade

Atul Deodhar

115 papers receiving 3.0k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

2017 272 citations Désirée van der Heijde, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

2021 159 citations Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases profile →
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Atul Deodhar United States	27	2.5k	1.7k	1.0k	243	204	125	3.0k
Feng Huang China	26	2.1k 0.9×	1.2k 0.7×	827 0.8×	211 0.9×	178 0.9×	102	3.0k
Nigil Haroon Canada	28	2.4k 1.0×	1.4k 0.8×	890 0.9×	227 0.9×	165 0.8×	123	2.9k
F. van Gaalen Netherlands	31	2.9k 1.2×	1.4k 0.8×	606 0.6×	504 2.1×	138 0.7×	133	3.6k
Rafael Valle‐Oñate Colombia	18	1.6k 0.6×	799 0.5×	592 0.6×	128 0.5×	120 0.6×	59	1.9k
Sławomir Jeka Poland	22	1.1k 0.5×	1.1k 0.6×	409 0.4×	114 0.5×	203 1.0×	98	2.2k
John Han United States	17	1.9k 0.7×	754 0.4×	831 0.8×	133 0.5×	145 0.7×	20	2.3k
H. Kellner Germany	15	1.9k 0.8×	825 0.5×	762 0.7×	89 0.4×	158 0.8×	52	2.3k
Jianhua Xu China	26	1.2k 0.5×	717 0.4×	321 0.3×	128 0.5×	99 0.5×	91	1.9k
J. Christiaan van Denderen Netherlands	16	1.8k 0.7×	441 0.3×	631 0.6×	127 0.5×	71 0.3×	26	2.2k
Millicent Stone Canada	25	1.7k 0.7×	823 0.5×	567 0.5×	345 1.4×	117 0.6×	43	2.1k

Countries citing papers authored by Atul Deodhar

Since Specialization

Citations

This map shows the geographic impact of Atul Deodhar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atul Deodhar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atul Deodhar more than expected).

Fields of papers citing papers by Atul Deodhar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atul Deodhar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atul Deodhar. The network helps show where Atul Deodhar may publish in the future.

Co-authorship network of co-authors of Atul Deodhar

This figure shows the co-authorship network connecting the top 25 collaborators of Atul Deodhar. A scholar is included among the top collaborators of Atul Deodhar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atul Deodhar. Atul Deodhar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deodhar, Atul, Victoria Navarro‐Compán, Denis Poddubnyy, et al.. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 11(1). e005081–e005081. 2 indexed citations

Marzo‐Ortega, Helena, Victoria Navarro‐Compán, Maureen Dubreuil, et al.. (2025). Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. RMD Open. 11(4). e006013–e006013.

Deodhar, Atul, Jerzy Supronik, Alan Kivitz, et al.. (2024). Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study. Arthritis & Rheumatology. 77(2). 163–170. 1 indexed citations

Deodhar, Atul, Servet Akar, Jeffrey R. Curtis, et al.. (2024). Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis. Advances in Rheumatology. 64(1). 87–87. 1 indexed citations

Mease, Philip J., et al.. (2024). Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials. Rheumatology and Therapy. 11(6). 1551–1567. 1 indexed citations

Rudwaleit, Martín, Matthew Brown, Nigil Haroon, et al.. (2024). P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Rahman, Proton, Iain B. McInnes, Atul Deodhar, et al.. (2024). Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical Rheumatology. 43(5). 1591–1604.

Rudwaleit, Martín, Atul Deodhar, Lars Bauer, et al.. (2024). Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status. RMD Open. 10(2). e003884–e003884.

Danve, Abhijeet, Marina Magrey, & Atul Deodhar. (2024). An update on the management of axial spondyloarthritis for sports medicine professionals. BMC Sports Science Medicine and Rehabilitation. 16(1). 211–211.

10.

Ritchlin, Christopher T., Philip J. Mease, Wolf‐Henning Boehncke, et al.. (2024). Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical Rheumatology. 43(8). 2551–2563. 1 indexed citations

11.

Baraliakos, Xenofon, J. Sieper, Robert D. Inman, et al.. (2024). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Research & Therapy. 26(1). 197–197. 2 indexed citations

12.

McGonagle, Dennis, Iain B. McInnes, Atul Deodhar, et al.. (2023). Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology. 5(4). 227–240. 4 indexed citations

13.

Deodhar, Atul, Huji Xu, Xenofon Baraliakos, et al.. (2021). Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases. 80(8). 1004–1013. 159 indexed citations breakdown →

14.

Deodhar, Atul, Philip J. Mease, Proton Rahman, et al.. (2020). Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy. 8(1). 135–150. 11 indexed citations

15.

Kvien, Tore K, Philip G. Conaghan, Laure Gossec, et al.. (2020). Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials. Arthritis Care & Research. 74(5). 759–767. 11 indexed citations

16.

Deodhar, Atul, Soumya D. Chakravarty, Chris Cameron, et al.. (2020). A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clinical Rheumatology. 39(8). 2307–2315. 20 indexed citations

17.

Sieper, J., Martín Rudwaleit, Désirée van der Heijde, et al.. (2014). LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL. Clinical and Experimental Rheumatology. 32(5). 785–786. 1 indexed citations

18.

Inman, Robert D., Atul Deodhar, Jürgen Braun, et al.. (2013). Achieving Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein Major Improvement and Inactive Disease in Patients with Ankylosing Spondylitis after Treatment with Golimumab is Associated with Normalized Health Related Quality of Life: 2-Year Results from GO-RAISE. Lara D. Veeken. 40(6). 1012–1012. 1 indexed citations

19.

Gensler, Lianne S., et al.. (2012). The “Knowns” and “Unknowns” of Biologic Therapy in Ankylosing Spondylitis. The American Journal of the Medical Sciences. 343(5). 360–363. 4 indexed citations

20.

Heijde, D. van der, Atul Deodhar, Laura Diekman, et al.. (2010). GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS : 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY. Clinical and Experimental Rheumatology. 28(4). 618–618. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact